Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa

Hannah Kibuuka, David Guwatudde, Robert Kimutai, Lucas Maganga, Leonard Maboko, Cecilia Watyema, Fredrick Sawe, Douglas Shaffer, Dickson Matsiko, Monica Millard, Nelson Michael, Fred Wabwire-Mangen, Merlin Robb, Hannah Kibuuka, David Guwatudde, Robert Kimutai, Lucas Maganga, Leonard Maboko, Cecilia Watyema, Fredrick Sawe, Douglas Shaffer, Dickson Matsiko, Monica Millard, Nelson Michael, Fred Wabwire-Mangen, Merlin Robb

Abstract

Background: HIV vaccine trials generally require that pregnant women are excluded from participation, and contraceptive methods must be used to prevent pregnancy during the trial. However, access to quality services and misconceptions associated with contraceptive methods may impact on their effective use in developing countries. We describe the pattern of contraceptive use in a multi-site phase I/IIa HIV Vaccine trial in East Africa (Uganda, Kenya and Tanzania) and factors that may have influenced their use during the trial.

Methods: Pregnancy prevention counseling was provided to female participants during informed consent process and at each study visit. Participants' methods of contraception used were documented. Methods of contraceptives were provided on site. Pregnancy testing was done at designated visits during the trial. Obstacles to contraceptive use were identified and addressed at each visit.

Results: Overall, 103 (31.8%) of a total of 324 enrolled volunteers were females. Female participants were generally young with a mean age of 29(+/-7.2), married (49.5%) and had less than high school education (62.1%). Hormonal contraceptives were the most common method of contraception (58.3%) followed by condom use (22.3%). The distribution of methods of contraception among the three sites was similar except for more condom use and less abstinence in Uganda. The majority of women (85.4%) reported to contraceptive use prior to screening. The reasons for not using contraception included access to quality services, insufficient knowledge of certain methods, and misconceptions.

Conclusion: Although hormonal contraceptives were frequently used by females participating in the vaccine trial, misconceptions and their incorrect use might have led to inconsistent use resulting in undesired pregnancies. The study underscores the need for an integrated approach to pregnancy prevention counseling during HIV vaccine trials.

Trial registration: ClinicalTrials.gov NCT00123968.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. UNAIDS/WHO. AIDS Epidemic Update. 2006 Available: . Accessed 2008 Mar 05.
    1. Guinan ME, Leviton L. Prevention of HIV infection in women: Overcoming barriers. JAMWA. 1995;50(3&4):74–77.
    1. Mills E, Nixon S, Singh S, Dolma S, Nayyar A, et al. Enrolling Women into HIV Preventive Trials: an ethical imperative but a logical Challenge. PLoS Med. 2006;3(3):e94.
    1. Wassener DR, Barsdorf NW, Richter LM. Gender and HIV Vaccine trials: Ethics and Social science issue. Harvard health Policy Review. 2005;6(1):124–129.
    1. Nakkazi E. Strategic thinking: Cultural barriers keeping Kenyan and Ugandan women out of AIDS vaccine trials. 2003 The East African Aug 4. Available: . Accessed 2008 Mar 05.
    1. Wakasiaka S. Challenges recruiting women into Trials. In: Patricia Kahn., editor. AIDS Vaccine Handbook: Global Perspectives. New York: AIDS Vaccine Advocacy Coalition; 2005. pp. 179–181.
    1. Raymond EG, Taylor D, Cates W, Tolley E, Borasky D, Cancel A, et al. Pregnancy in Effectiveness Trials of HIV Prevention Agents. Sexually Transmitted Diseases. 2007;34(12):1035–1039.
    1. IAVI database of preventive AIDS vaccines in human trials. New York, International AIDS Vaccine Initiative. 2008 Available: http/ . Accessed 2008 March 05.
    1. Weidie PJ, Mastro T, Grant AD, Nkengasong J, Macharia D. HIV/AIDS treatment and HIV vaccines for Africa. The lancet. 2002;359(9325):2261–2267.
    1. Cao H, Kaleebu P, Hom D, Floers J, Agrawal D, et al. Immunogenicity of a Recombinant Human Immunodeficiency virus(HIV)-Canarypox Vaccine in HIV-Seronegative Ugandan Volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study. JID 15; 2003;187:887–895.
    1. Seiber E, Bertarand JT, Sullivan TM. Changes in Contraceptive Method Mix In Developing Countries. International Family Planning Perspectives. 2007;33(3):177–123.
    1. Uganda HIV /AIDS Sero-Behavioral Survey. 2004–2005 Available: . Accessed 2008 July 22.
    1. Kenya Demographic and Health survey, Key findings. 2003 Available: . Accessed 2008 July 22.
    1. Biddle A, Fapohunda BM. Covert contraceptive use prevalence motivations and consequences. Studies in family planning. 1998;29(4):360–372.
    1. When women hide contraceptive use. Network 22: No. 2: 2002 Available: contr.htm. Accessed 2008 July 28.
    1. Kamau RK, Karanja J, Sekadde-Kigondu, et al. Barriers to Contraceptives use in Kenya. East African Medical Journal. 1996;73(10):651–9.
    1. Agyei WK, Migadde M. Demographic and sociocultural factors influencing contraceptive use in Uganda. Journal Biosocial Science. 1995;27(1):47–60.
    1. Lane T. Contraceptive use around the globe, an update. International Family Planning Perspectives. 2004;30(2)
    1. Lande R, Richey C. Expanding services for injectables. Population reports Series K, No 6 2006
    1. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, et al., editors. Contraceptive Technology, 18th ed. New York: Ardent Media; 2004.
    1. Fertility rates for Uganda, Kenya and Tanzania. 2006 Available at . Accessed on 24th Jan 2008.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere